Arkenau, H., Patel, S., Oh, D. (2026). A phase I/IIa study to evaluate the safety and tolerability, activity, and PK of a potential novel CNTN4-targeted checkpoint inhibitor, EP0089, in patients with advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps2688